{"entity":{"id":"nct07145333","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","aka":[],"tldr":"A phase 2/3 trial of Topotecan in small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.","summary":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT07145333 by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, with 600 participants enrolled, started 2025-08-12 and due to reach its primary completion in 2026-09-18. Interventions recorded: Topotecan - usual and Topotecan - study.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07145333","url":"https://clinicaltrials.gov/study/NCT07145333"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["topotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07145333","phase":"2/3","setting":"Explore the Relationship Between Single Nucleotide Polymorphisms and Topotecan Response and Toxicity in Patients With Small Cell Lung Cancer.","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","enrolled":600,"outcomes":[]},"route":"/trials/nct07145333/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"}]}}